pioglitazone has been researched along with Dermatosclerosis in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are only a few studies on the treatment of dermal fibrosis with sustained-release drugs." | 5.51 | Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis. ( Arita, T; Asai, J; Jo, JI; Kanemaru, M; Katoh, N; Kawai-Ohnishi, M; Tabata, Y; Tsutsumi, M; Wada, M, 2019) |
| "There are only a few studies on the treatment of dermal fibrosis with sustained-release drugs." | 1.51 | Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis. ( Arita, T; Asai, J; Jo, JI; Kanemaru, M; Katoh, N; Kawai-Ohnishi, M; Tabata, Y; Tsutsumi, M; Wada, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanemaru, M | 1 |
| Asai, J | 1 |
| Jo, JI | 1 |
| Arita, T | 1 |
| Kawai-Ohnishi, M | 1 |
| Tsutsumi, M | 1 |
| Wada, M | 1 |
| Tabata, Y | 1 |
| Katoh, N | 1 |
1 other study available for pioglitazone and Dermatosclerosis
| Article | Year |
|---|---|
Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis.
Topics: Animals; Bleomycin; Cell Differentiation; Delayed-Action Preparations; Disease Models, Animal; Drug | 2019 |